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ABSTRACT 
As part of its Single Technology Appraisal process, the National Institute for Health and Care 
Excellence (NICE) invited the manufacturer of olaparib (AstraZeneca) to submit evidence on the 
clinical effectiveness and cost-effectiveness of olaparib for the maintenance treatment of BRCA1/2 
mutated (BRCAm), relapsed, platinum-sensitive (PSR) ovarian, fallopian tube and peritoneal cancer in 
people whose relapsed disease has responded to platinum-based chemotherapy. The Evidence Review 
Group (ERG) produced a critical review of the evidence contained within WKHFRPSDQ\¶VVXEPLVVLRQ
(CS) to NICE.  
 
The clinical evidence related to one Phase II, double-blind randomised controlled trial which recruited 
265 patients with platinum-sensitive recurrent serous ovarian cancer (OC) regardless of BRCAm 
status. Patients received 400mg olaparib b.d. or matched placebo. In the whole population, the 
primary endpoint of progression-free survival (PFS) was met (hazard ratio= 0.35; 95% confidence 
interval (CI) 0.25 to 0.49, p<0.01) for olaparib versus placebo. The BRCAm subgroup analysis (added 
after the study commenced but one month before the primary analysis was undertaken) reported an 
HR for PFS of 0.18 (95% CI 0.10 to 0.31, p<0.0001) for olaparib versus placebo, though interaction 
tests appeared inconclusive. Overall survival was not statistically significant in the whole group (HR 
0.88 (95% CI 0.64 to 1.21, p=0.44) or the BRCAm subgroup (0.73 (95% CI 0.45 to 1.17, p=0.19), 
though treatment switching may have confounded results. The exclusion of data from sites allowing 
crossover resulted in an HR of 0.52 (95% CI 0.28 to 0.97, p=0.039) in the BRCAm group. Health-
related quality of life measures were not significantly different between groups. All post hoc 
exploratory outcomes (time to treatment discontinuation/death, time to first subsequent therapy/death, 
and time to second subsequent therapy/death) were statistically significantly better in the olaparib arm 
in the whole population and the BRCAm subgroup analyses. Adverse events were more frequent for 
olaparib, but were largely minor or manageable.  
 
The company¶V semi-Markov model assessed the cost-effectiveness of olaparib versus routine 
surveillance in patients with BRCAm PSR OC from an NHS/PSS perspective over a lifetime horizon. 
The model suggested that the incremental cost-effectiveness ratio (ICER) for olaparib versus routine 
surveillance is expected to be approximately £49,146 per quality-adjusted life year (QALY) gained. 
The ERG did not coQVLGHUWKHFRPSDQ\¶Vcost-effectiveness estimates to be credible. Additional ERG 
analyses suggested that the ICER is likely to be more than £92,214 per QALY gained. Additional 
analyses provided by the company in patients who have received 3 or more lines of chemotherapy 
suggested a more favourable cost-effectiveness profile for olaparib. The NICE Appraisal Committee 
recommended olaparib this subgroup provided the cost of olaparib for people who remain on 
treatment after 15 months will be met by the company. 
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KEY POINTS FOR DECISION-MAKERS 
x The supporting clinical evidence for olaparib was a subgroup analysis of a Phase II trial, 
considered to be at moderately high risk of bias overall. The BRCAm subgroup was 
considered clinically plausible, but interaction tests were inconclusive. PFS was significantly 
better for patients receiving olaparib (p<0.0001). OS was not significantly better (p=0.19) 
except in the cross-over adjusted analysis (p=0.039), though this analysis did not correct for 
unlicensed treatment with olaparib beyond PFS. 
x Additional work undertaken by the ERG suggested that the ICER for olaparib versus routine 
surveillance in BRCAm PSR OS patients who have received two or more lines of 
chemotherapy is likely to be greater than £92,214 per QALY gained.  
x The NICE Appraisal Committee concluded that the most plausible ICERs for olaparib versus 
routine surveillance in BRCAm PSR OC patients who have received three or more lines 
chemotherapy were £46,600 to £46,800 per QALY gained. 
x Olaparib was recommended within its marketing authorisation for treating adults with 
BRCAm PSR OC and whose disease has responded to platinum-based chemotherapy only if: 
they have had 3 or more courses of platinum-based chemotherapy, and; the drug cost of 
olaparib for people who remain on treatment after 15 months will be met by the company. 
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1. INTRODUCTION 
Health technologies must be shown to represent a clinically effective and cost-effective use of 
resources in order to be recommended for use within the NHS in England. The National Institute for 
Health and Care Excellence (NICE) is an independent organisation responsible for providing national 
guidance on promoting good health and preventing and treating ill health in priority areas with a 
significant impact. The NICE Single Technology Appraisal (STA) process usually covers new 
technologies within a single indication, shortly after they have received UK marketing authorisation 
[1]. Within this process, the company provides NICE with a written submission that summarises the 
FRPSDQ\¶V HVWLPDWHVRI WKH FOLQLFDO HIIHFWLYHQHVVDQGFRVW-effectiveness of the technology, together 
with an executable health economic model. 7KH FRPSDQ\¶V VXEPLVVLRQ &6 is reviewed by an 
external organisation independent of NICE, the Evidence Review Group (ERG), which consults with 
clinical specialists and produces an ERG report. After consideration of the CS, the ERG report and 
testimony from experts and other stakeholders, the NICE Appraisal Committee formulates 
preliminary guidance in the form of an Appraisal Consultation Document (ACD) which indicates the 
&RPPLWWHH¶V initial recommendations on the use of the technology. Stakeholders are subsequently 
invited to comment on the submitted evidence and the ACD, after which a subsequent ACD may be 
produced or a Final Appraisal Determination (FAD) is issued, which is open to appeal. An ACD is not 
produced when the technology is recommended without restriction; in such instances, the FAD is 
produced directly. This paper presents a summary of the ERG report [2] and subsequent analyses [3-
5] for the STA of olaparib for the maintenance treatment of BRCA1/2 mutated (BRCAm), relapsed, 
platinum-sensitive (PSR) ovarian, fallopian tube and peritoneal cancer in people whose relapsed 
disease has responded to platinum-based chemotherapy, and the subsequent development of the NICE 
guidance for the use of this drug in England [6]. Full details of all relevant appraisal documents can be 
found on the NICE website (https://www.nice.org.uk/guidance/indevelopment/ta381/documents).  
 
2. THE DECISION PROBLEM 
Ovarian cancer (OC) represents a group of tumours that arise from diverse types of tissue contained in 
the ovary. The most common type of OC arises from epithelial cells on the surface of the ovary, and 
can often spread to any surface within the abdominal cavity including the fallopian tubes and 
peritoneal cavity. The symptoms of OC commonly include persistent abdominal distension, early 
satiety and/or loss of appetite, pelvic or abdominal pain and increased urinary urgency and/or 
frequency [7]. Approximately 6,100 women are diagnosed with OC in England each year [8]. 
Incidence increases with age and most cases are diagnosed in older postmenopausal women. Most 
OCs are sporadic. However, the presence of BRCA mutations account for more than 10% of all OCs 
and carriers of BRCA mutations have an increased lifetime risk of developing breast cancer and OC. 
In England and Wales, the 5-year survival rate is approximately 46%, however, prognosis is 
considerably worse for patients with advanced disease [8]. Approximately 10±15% of women 
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presenting with advanced disease achieve long-term remission through chemotherapy. However, 
following initial response to treatment, the majority of patients subsequently relapse. 
 
2.1 Current treatment 
There are currently no licensed therapies for the maintenance treatment of PSR OC. Prior to January 
2015, bevacizumab was available in England as a maintenance therapy; this is no longer routinely 
available through the Cancer Drugs Fund (CDF) in the relapsed setting. Current care involves routine 
surveillance, with further chemotherapy given upon relapse. Surveillance typically involves routine 
outpatient appointments to assess for symptomatic disease progression. Cancer antigen 125 (CA125), 
a serum tumour marker, may be used to detect relapse in OC, although the benefits of routine 
measurement are disputed and its use across England is variable [9]. In people whose disease relapses 
following initial therapy, NICE recommends paclitaxel in combination with a platinum compound in 
platinum-sensitive or partially platinum-sensitive disease; pegylated liposomal doxorubicin 
hydrochloride in partially platinum-sensitive, platinum-resistant or platinum-refractory disease; 
paclitaxel alone in platinum-refractory or platinum-resistant disease, and; topotecan in platinum-
refractory or platinum-resistant disease for people for whom pegylated liposomal doxorubicin 
hydrochloride and single-agent paclitaxel are considered inappropriate [10]. 
 
Olaparib (Lynparza®) is a potent inhibitor of poly (ADP-ribose) polymerase (PARP)-1, PARP-2 and 
PARP-3. Olaparib is licensed for the maintenance treatment of adult patients with PSR BRCAm 
(germline and/or somatic) high grade serous epithelial ovarian, fallopian tube, or primary peritoneal 
cancer who are in complete or partial response to platinum-based chemotherapy [11]. The 
recommended dose of olaparib is 400mg (eight 50mg capsules) b.d. Treatment should be continued 
until disease progression; treatment interruptions and dose reductions may be used to manage adverse 
reactions [11]. As of June 2016, olaparib had not been listed on the British National Formulary (BNF) 
[12]. The original anticipated NHS list price was £3,950.00 per pack (448 capsules) [13]. During the 
appraisal, a Patient Access Scheme (PAS) was agreed whereby the cost of olaparib for people who 
remain on treatment for more than 18 months will be met by the company. This was subsequently 
reduced to 15 months and a price of £3,550 per pack was agreed. All results presented here include 
the original 18-month PAS and original list price. 
 
In order to receive olaparib, patients must have confirmation of BRCAm. Current NICE guidelines 
recommend BRCA testing for women with OC in whom the combined BRCA1/2m carrier probability 
is 10% or more [14]. Currently, the use of BRCAm testing across England remains variable. 
 
In November 2014, NICE issued a final scope to appraise the clinical effectiveness and cost-
effectiveness of olaparib within its licensed indication for the maintenance treatment of BRCA1/2m, 
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PSR ovarian, fallopian tube and peritoneal cancer in people whose relapsed disease has responded to 
platinum-based chemotherapy [15]. 
 
3. INDEPENDENT ERG REVIEW 
The company (AstraZeneca) provided a submission to NICE on the clinical effectiveness and cost-
effectiveness of olaparib for the maintenance treatment of BRCA1/2m PSR OC [13]. This submission 
was critically appraised by the ERG. In addition, the ERG identified areas requiring clarification, for 
which the company provided additional evidence prior to completion of the ERG report [2, 16].  
 
3.1.1 Clinical evidence submitted by the company 
The CS included an unpublished systematic review of studies in patients with OC of any BRCAm 
status. The scope of this review was wider than that required by the decision problem. One relevant 
study was identified for inclusion (Study 19 [17]).  
 
3.1.1.1 Clinical trial design 
Population and trial design: Study 19 was a pivotal Phase II, double-blind RCT. The study recruited 
265 patients aged 18 years or older, with a histological diagnosis of recurrent, high-grade (grade 2 or 
3) serous OC (including primary peritoneal or fallopian tube cancer) that was platinum-sensitive 
(progression >6 months) as determined by response to the most recent round of chemotherapy and at 
least one previous round (not necessarily sequential rounds), and regardless of BRCAm status. Patients 
who had received previous PARP inhibitor (PARPi) therapy were excluded. Patients had to have an 
Eastern Co-operative Oncology Group (ECOG) SHUIRUPDQFHVWDWXV, a life expectancy of at least 16 
weeks and a CA125 measurement below the upper limit of normal, or if above, not significantly rising 
over time.  
 
Intervention and comparator: Patients were randomised by an interactive voice response system 
(IVRS) to 400mg olaparib b.d. or matched placebo. Interruptions and dose reductions were permitted 
to address toxicity or adverse events (AEs), but re-treatment was not allowed. Continuation of 
treatment was permitted for patients who were still benefitting. Some concomitant medications were 
allowed, and patients in the placebo arm could crossover to receive a PARPi after the study endpoint 
was reached.  
 
Outcomes: The primary outcome was progression-free survival (PFS) as assessed by the Response 
Evaluation Criteria in Solid Tumours (RECIST) criteria or death. Pre-specified secondary outcomes 
relevant to the scope included overall survival (OS), AEs and health-related quality of life (HRQoL) 
by the Trial Outcome Index (TOI), the Functional Assessment of Cancer Therapy - Ovarian (FACT-
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O) and the FACT/NCCN Ovarian Symptom Index (FOSI). Additional post hoc exploratory analyses 
were reported for the safety population, including: time to treatment discontinuation/death (TTD/D), 
time to first subsequent therapy/death (TFST/D) and time to second subsequent therapy/death 
TSST/D (Figure 1). Only TFST/D was listed in the NICE scope, with TSST/D presented as a proxy 
for PFS2. AEs were graded according to National Cancer Institute Common Terminology Criteria for 
Adverse Events (NCI-CTCAE) version 3.0 [18].  
 
Figure 1: Outcome measurement in Study 19 
[INSERT FIGURE 1 HERE] 
 
Analysis plan: The pivotal data for this assessment was a subgroup analysis of BRCAm patients from 
Study 19 [13, 19]. The testing of all patients for BRCAm status, a subgroup analysis of PFS in BRCAm 
patients, and a global interaction test were added to the statistical plan approximately one month 
before the PFS data cutoff (DCO) point was reached (June 2010). This replaced the subgroup analysis 
of patients who had homologous-recombination-deficient (HRD) tumours (of which BRCA mutations 
are a subset), as an HRD test was not developed in time. Additional analyses of all other clinical 
endpoints in this subgroup were added to the analysis plan after the DCO, in consultation with the 
European Medicines Agency (EMA). Changes were also made to the timing of OS analyses after the 
DCO. In the whole population analysis, OS was analysed at two main points: (i) at the same time as 
the PFS analysis, and; (ii) at an interim point when the data were 58% mature.  
 
3.1.1.2 Clinical study results 
Patient characteristics: The most notable imbalances in patient characteristics related to objective 
response to the most recent platinum-based chemotherapy, and to a lesser extent, in ECOG 
performance status. Adjustments for imbalances were applied in Cox proportional hazards model 
analyses in the full analysis set (FAS); it was unclear if adjustment was applied to the BRCAm 
subgroup. 
 
PFS: In the whole population analysis, the primary study endpoint was met, with a hazard ratio (HR) 
for PFS of 0.35 (95% confidence interval [C.I]. 0.25 to 0.49, p<0.01) for olaparib versus placebo. 
Median PFS was 8.4 months for olaparib versus 4.8 months for placebo (95% CI not reported [NR]). 
The BRCAm subgroup analysis reported an HR for PFS of 0.18 (95% CI 0.10 to 0.31, p<0.0001) for 
olaparib versus placebo; median PFS was 11.2 months for olaparib (95% CI WR³QRWFDOFXODEOH´
versus 4.3 months for placebo (95% CI 3.0 to 5.4). A treatment-subgroup interaction test was not 
presented within the CS but was reported in the Clinical Study Report (CSR) and the European Public 
Assessment Report (EPAR); each reports a significant interaction for BRCAm (p=0.030 or p=0.025, 
respectively) when considered alone, but a non-significant interaction (p=0.15647 or p=0.142, 
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respectively) when a global test adding treatment interaction terms for all non-treatment covariates 
was performed [20, 21]. 
OS: Within the whole population, OS was not significantly different between groups at either analysis 
point. The HR for death was 0.94 (95% CI 0.63 to 1.39; p=0.75) for olaparib versus placebo (median 
OS 29.7 months versus 29.9 months respectively, 95% CI NR) at the June 2010 DCO [17]. At 58% 
OS data maturity (November 2012), the HR for death was 0.88 (95% CI 0.64 to 1.21, p=0.44) for 
olaparib versus placebo, with a median survival of 29.8 months (95% CI 27.2 to 35.7) in the olaparib 
arm versus 27.8 months (95% CI 24.4 to 34.0) in the placebo arm [20, 21]. For the BRCAm subgroup, 
OS was reported only at the November 2012 DCO (52% maturity); the HR for death was 0.73 (95% 
CI 0.45 to 1.17, p=0.19) for olaparib versus placebo. Median OS was 34.9 months in the olaparib 
group and 31.9 months in the placebo group. A crossover analysis within the BRCAm group in which 
sites allowing placebo group crossover to PARPis reported a significant OS difference (HR=0.52, 
95% CI 0.28 to 0.97, nominal p=0.039) [22]. No correction was applied for patients in the olaparib 
arm who continued to receive olaparib beyond disease progression. 
 
HRQoL: Study 19 reported ³QRVLJQLILFDQWGLIIHUHQFHLQLPSURYHPHQWUDWHVRUWLPHWRZRUVHQLQJRI
TOI, FOSI or Total FACT-2´ and it was concluded that HRQoL was not negatively impacted during 
therapy [23]. 
 
Other outcomes: All post hoc exploratory outcomes (TTD/D, TFST/D and TSST/D) were statistically 
significant for the whole population and the BRCAm subgroup. In the whole population, the HR for 
TTD/D was 0.39 (95% CI 0.30 to 0.51) for olaparib versus placebo, and 0.36 (95% CI 0.24 to 0.53) 
for olaparib versus placebo in the BRCAm subgroup. In the whole population, the HR for TFST/D was 
0.41 (95% CI 0.31 to 0.54) for olaparib versus placebo, and 0.33 (95% CI 0.22 to 0.50) for olaparib 
versus placebo in the BRCAm subgroup. In the whole population, the HR for TSST/D was 0.54 (95% 
CI 0.41 to 0.72) for olaparib versus placebo, and 0.44 (95% CI 0.29 to 0.67) for olaparib versus 
placebo in the BRCAm subgroup. 
 
AEs occurred more often in the olaparib group, but were largely minor and manageable with dose 
reductions or interruptions. More patients receiving olaparib suffered severe AEs such as fatigue, 
anaemia and neutropenia compared with placebo. Serious AEs occurred in 21.6% of olaparib patients 
versus 9.7% of placebo patients. These included anaemia, small bowel obstruction, dyspnoea and 
gastritis. 
 
3.1.2 Critique of clinical effectiveness evidence and interpretation 
3.1.2.1 Critique of systematic review 
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Adaptations to the systematic review were made by the company to bring it in line with the NICE 
scope. Whilst unclear from the CS, clarifications provided by the company suggest that the review 
was well conducted. The ERG concluded that all relevant evidence had been identified. 
3.1.2.2 Critique of clinical evidence  
Study 19 had several limitations, both methodologically and with respect to its relevance to the 
decision problem. 
 
Population: The inclusion criteria for the FAS were considered broadly appropriate by the ERG and 
their clinical advisors [11]. Two ERG advisors thought the criteria requiring stable CA125 status to be 
reasonable, and considered that CA125 status would likely be used in clinical practice as this 
biomarker is used to monitor response to chemotherapy. Baseline imbalances were considered likely 
to be due to problems with the IVRS which led to mis-stratification of patients; whilst these were 
corrected using Cox model analyses for the FAS, it remained unclear whether all BRACm analyses 
were also adjusted. 
 
The BRCAm subgroup was considered clinically relevant, but the study used both germline (blood 
test) and tumour (tissue sample test) BRCAm testing to select patients. Tumour testing is not routinely 
performed in England and it is unclear whether this will be possible on a large scale. Consequently, 
this may potentially lead to problems regarding generalisability. 
 
Intervention: The intervention was considered largely appropriate, with the exception of the 
continuation of olaparib beyond progression (which is not in accordance with the licence), and the 
assessment of progression (halting treatment in most cases) using RECIST rather than CA125 (which 
generally indicates progression before RECIST). These factors are likely to mean that treatment was 
administered in the trial for longer than would be the case in usual clinical practice in England.  
 
Comparator: The ERG concluded that the comparator reflected clinical practice. Data on differences 
in concomitant treatments (e.g. ascites drainage, pain relief) between groups were not presented. 
 
Outcomes: The primary outcome was considered appropriate, though it was noted that PFS is a proxy 
for OS, and that OS is the most relevant outcome. The ERG argued that as Study 19 is being used as 
pivotal evidence, it should conform to EMA guidelines for Phase III trials [24]; these state that PFS 
should be supported by a trend toward OS benefit, or outcomes such as PFS2 or time to next line 
therapy. In Study 19, TFST/D and TSST/D were considered by the ERG to be suitable supporting 
endpoints instead of PFS2, despite not being listed in the NICE scope. However, the clinical advisors 
were concerned that practice in the countries included in Study 19 may be to commence subsequent 
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therapy earlier than in England, thus truncating these outcomes. Furthermore, these outcomes were 
added to the study plan after PFS data had been collected, hence they are at high risk of bias. 
 
Conversely, continuation of treatment beyond PFS and the use of RECIST criteria rather than CA125 
means that TTD/D and PFS may be longer than would be expected in clinical practice. Other 
outcomes such as TFST/D, TSST/D, OS and AEs may have been affected by the increased dose 
allowed in the trial, unblinding of study participants, and by placebo group crossover. Generalisability 
was therefore a concern to the ERG.  
 
AE measurement was largely adequate, despite a lack of clarity in the methods of elicitation. The 
choice of HRQoL measures appeared appropriate, though a preference-based measure was not used 
and measurement was only performed during the treatment phase of the trial.  
 
Study design: The multiple changes to the statistical analysis plan, particularly the timing of OS 
measurement and the addition of the BRCAm subgroup analyses, were a matter of concern as they 
were performed post hoc. The company¶VUDWLRQDOHIRUVHOHFWLQJthe BRCAm subgroup was thought to 
have clinical plausibility by the (5*¶Vclinical advisors, though interaction tests were inconclusive. 
Based on published quality assessment criteria [25], the ERG scored the study as low risk for 4 
domains (allocation concealment, imbalances in dropouts between groups, outcome reporting bias and 
analysis methods), but high risk for randomisation (due to problems with the IVRS) and balance 
between groups in prognostic factors at baseline, and unclear risk for blinding as some patients were 
unblinded under an emergency protocol. 
 
As these biases and relevance issues may operate in unknown directions and to unknown extents, 
together with the small sample size of the study and subgroup analyses, the ERG concluded that the 
study results were associated with considerable uncertainty in relation to their accuracy and 
generalisability. To compound these issues further, the history of changes to the study protocol and 
the post hoc definition of the BRCAm subgroup and inconclusive interaction tests means that the 
hypothesis that olaparib has superior efficacy in BRCAm patients compared with other patients had 
not been robustly tested or proved. The ERG noted that a Phase III trial of olaparib in BRCAm OC 
patients was ongoing (clinicaltrials.gov identifier - NCT01874353) and would provide the required 
FRQILUPDWLRQRIWKHVWXG\¶VUHVXOWV. The lack of conclusive evidence to support an OS advantage for 
olaparib does not detract from the benefits inherent to a postponement of PFS, but does make it 
difficult to conclude whether olaparib confers a survival benefit or not. 
 
3.2 Cost-effectiveness evidence submitted by the company 
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The company submitted a de novo health economic model to assess the cost-effectiveness of olaparib 
versus routine surveillance in patients with BRCAm PSR OC7KHFRPSDQ\¶Veconomic analysis was 
comprised of two related evaluations: 
(i) The base case economic evaluation of olaparib maintenance treatment versus routine 
surveillance in patients with BRCAm PSR OC. This excludes the costs of BRCAm testing and 
considers costs and benefits relating to the index BRCAm OC patient. 
(ii) A broader economic evaluation that also accounts for: (a) the costs of BRCAm testing in 
BRCAm PSR OC patients, and; (b) the costs and benefits of expanding BRCAm testing to 
family members of relapsed BRCAm OC patients undergoing BRCAm testing as a prerequisite 
in consideration of olaparib as a potential treatment option. This analysis considers costs and 
benefits relating to the index BRCAm OC patient and family members.  
 
7KH FRPSDQ\¶V EDVH FDVH DQDO\VLV DGRSWV D VHPL-Markov approach and evaluates costs and health 
outcomes from a National Health Service (NHS) and Personal Social Services (PSS) perspective over 
a lifetime horizon (15 years), discounted at a rate of 3.5% per year. The FRPSDQ\¶Vmodel (Figure 2) 
includes five health states: (i) progression-free (on maintenance treatment); (ii) progression-free 
(discontinued maintenance treatment); (iii) first subsequent chemotherapy (on treatment or 
discontinued); (iv) second subsequent chemotherapy (on treatment or discontinued), and; (v) dead. 
Transitions between progressive states are modelled using parametric survivor functions fitted to 
time-to-event data together with fixed estimates of the proportion of these progression events which 
are deaths. Clinical input parameters were estimated using data from the Study 19 BRCAm subgroup 
[19]. For the progression-free states, health utilities were mapped from the FACT-O to the Euroqol 
EQ-5D [26]; utilities for subsequent states were sourced from a previous NICE submission [27]. 
Resource use estimates were based on Study 19 [19], previous appraisals [28], clinical guidelines 
[14], literature [29-31] and assumptions. Unit costs were derived from NHS Reference Costs 2013-14 
[32], the Personal Social Services Research Unit (PSSRU) [33], the NHS Commercial Medicines Unit 
(CMU) [34] and the BNF [12]. The additional costs and benefits of BRCAm testing within the 
secondary analysis were taken from the cost-effectiveness report published as part of the NICE 
familial breast cancer guideline [14]. The CS argues that olaparib satisfies N,&(¶V FULWHULD IRU OLIH-
extending therapies at the end of life (EoL) [35]. 
 
)LJXUH&RPSDQ\¶VPRGHOVWUXFWXUH 
[INSERT FIGURE 2 HERE] 
 
7KHSUREDELOLVWLFYHUVLRQRI WKH FRPSDQ\¶VPRGHO VXJJHVWV WKDWRODSDULE LV H[SHFWHG WRSURGXFHDQ
additional 0.90 quality-adjusted life years (QALYs) at an additional cost of £72,232 compared with 
routine surveillance; this corresponds to an incremental cost-effectiveness ratio (ICER) for olaparib 
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versus routine surveillance of approximately £49,146 per QALY gained. The deterministic model 
yielded a similar ICER of £49,826 per QALY gained. Assuming willingness-to-pay (WTP) thresholds 
of £30,000 and £50,000 per QALY gained, the probability that olaparib produces more net benefit 
than routine surveillance is approximately 0.02 and 0.52, respectively 7KH FRPSDQ\¶V VHFRQGDU\
analysis, which is based on five family pedigrees, suggests a lower average deterministic ICER for 
BRCAm testing plus olaparib versus routine surveillance without BRCAm testing of £39,343 per 
QALY gained. 
 
3.2.1 Critique of cost-effectiveness evidence and interpretation 
7KH (5* FULWLFDOO\ DSSUDLVHG WKH FRPSDQ\¶V HFRQRPLF DQDO\VLV DQG GRXEOH-programmed the 
FRPSDQ\¶VPRGHONo significant programming errors were found. However, the ERG had concerns 
regarding the model structure and the evidence used to inform WKHPRGHO¶Vparameters. 
 
3.2.1.1 Choice of model structure and use of outcomes data from Study 19 BRCAm subgroup 
The FRPSDQ\¶Vmodel assumes that all patients who survive their first subsequent therapy event (the 
³SURJUHVVLRQ-IUHH´SHULRGsubsequently receive a first subsequent chemotherapy and that all patients 
who survive the second subsequent therapy event subsequently receive a second course of 
chemotherapy. However, for some patients with advanced disease, chemotherapy may offer limited 
benefit and patients may instead receive supportive care. Furthermore, the model structurally limits 
the number of lines of subsequent chemotherapy to a maximum of two, yet within the Study 19 
BRCAm subgroup, more than 36% patients received three or more subsequent lines of therapy [13]. 
The ERG¶V PDLQ concerns surrounded the outcomes data included in the model and the range of 
evidence which had been excluded from it. The model is based on the time to first subsequent therapy 
or death (TFST/D ± from randomisation) and time to second subsequent therapy or death (TSST/D ± 
from first subsequent therapy) and survival within those states, with olaparib conferring a clinical 
benefit in delaying the time to first and second subsequent therapy, and as a consequence, delaying 
time to death. The modelled ³SURJUHVVLRQ-IUHH´ interval does not relate to the PFS endpoint, but is 
instead defined by TFST/D. PFS data are not used in the model. Both TFST/D and TSST/D were post 
hoc exploratory outcomes and may have been influenced by subjective decisions regarding future 
chemotherapy use, eligibility for treatment and loss of blinding within Study 19. The ERG also had 
concerns that the observed OS data from Study 19 were not directly used LQ WKHFRPSDQ\¶VPRGHO
Instead, the model applies the risk of death: (a) as a fixed proportion of time-dependent progression 
events upon leaving the progression-free and subsequent therapy states, and; (b) as a treatment-
independent time-to-event curve for all patients from entry into the second subsequent therapy state. 
Mortality is therefore captured as a conditional event for patients reaching different health states, 
rather than by fitting survivor functions to the Kaplan-Meier OS data.  
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The CS argued that their model structure better represents the benefits of maintenance treatments and 
the treatment pathway following relapse compared with a simple partitioned survival approach [13]. 
The ERG argued that the best model is that which: (a) represents clinical reality, and; (b) makes the 
best use of the evidence available. Excluding PFS, compounding multiple assumptions regarding 
mortality risks associated with specific health states within and between treatment groups, and 
limiting the treatment pathway to two lines of chemotherapy does not satisfy both of these criteria. 
 
3.2.1.2 Potential confounding of endSRLQWVXVHGLQWKHFRPSDQ\¶VPRGHO 
The model attempts to deal with placebo group crossover by assuming that the time from first 
subsequent therapy to second subsequent therapy or death, the probability that a second subsequent 
therapy event is death, and the time from second subsequent therapy to death, are independent of 
treatment. The company provided analyses in which placebo group OS was adjusted for treatment 
switching: (a) by excluding sites allowing placebo group crossover, and; (b) using a Rank Preserving 
Structural Failure Time Model (RPSFTM) [13, 16]. Kaplan-Meier curves produced using these 
methods each suggested an apparent OS benefit for olaparib versus placebo, but indicated little 
difference between the groups by around 3 years post-randomisation. As OS was not directly included 
as a model input, the impact of using these crossover-adjusted data on the cost-effectiveness of 
olaparib could not be assessed using the FRPSDQ\¶V model. No attempt was made to correct for 
confounding due to the continuation of olaparib beyond progression. 
 
3.2.1.3 Concerns regarding the methods for modelling of time-to-event outcomes 
According to the CS [13], the process for survival modelling was based on Latimer et al [36]. 
However, the justification for including baseline characteristics as covariates in the model-fitting 
process was neither justified nor explained, model discrimination did not appear to have included 
judgements about the plausibility of extrapolations, assumptions of proportional hazards appeared 
inappropriate, and sensitivity analyses using alternative survivor functions were not presented for 
outcomes except TFST/D. 
 
3.2.1.4 Discordance between model predictions and observed data from Study 19 
Model-predicted OS did not provide a good fit to the observed data, irrespective of whether crossover 
was adjusted for. Comparing the modelled and empirical OS curves indicated that: 
x The crossover-site-excluded (CSE) and RPSFTM-adjusted OS Kaplan-Meier curves were 
similar. 
x Despite adjustment, the gap between the olaparib and placebo curves appears to close, or 
nearly close, at around 3-years post-randomisation, irrespective of the crossover method 
applied. 
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x OS is reasonably predicted for olaparib for the first 2 years post-randomisation but is 
subsequently overestimated. 
x The model does not provide a good fit to the empirical placebo group data irrespective of the 
method of crossover adjustment. 
x Whilst the empirical OS data, both with and without crossover adjustment, suggest that the 
curves for olaparib and placebo intersect, or nearly intersect, at around 3 years post-
randomisation, this is not reflected in the model-predicted OS. Rather, it is around this 
timepoint within the model whereby WKH FRPSDQ\¶V PRGHO SUHGLFWV the greatest difference 
between the groups.  
 
These apparent biases in model-predicted OS are likely to be symptomatic of poorly fitting parametric 
models, inappropriate assumptions regarding proportional hazards, assumptions regarding the 
proportion of events which are deaths and the equivalence of time-to-event outcomes between groups 
following the first progression event. Overall, the ERG did not have confidence in the model results. 
 
&RQFHUQVUHJDUGLQJWKHQDWXUHRIWKHFRPSDULVRQPDGHZLWKLQWKHFRPSDQ\¶VVHFRQGDU\
analysis 
The secondary analysis compared BRCAm testing plus olaparib against no BRCAm testing and routine 
surveillance. However, the comparison that should have been made is BRCAm testing plus olaparib 
versus BRCAm testing plus routine surveillance; this was absent from the CS. Consequently, much of 
the apparent benefit of using olaparib suggested by the analysis is conflated with the benefits of 
BRCAm testing. 
 
3.3 Additional work undertaken by the ERG 
3.3.1 ERG exploratory analysis methods 
The ERG replicated the IPD from the Study 19 BRCAm subgroup using methods reported by Guyot et 
al [37] and fitted multiple candidate survivor functions to: (i) TTD/D; (ii) TFST/D; (iii) RPSFTM-
adjusted OS, and; (iv) CSE-adjusted OS. The analyses focussed on addressing two questions: (1) 
³What is the expected incremental OS gain for olaparib versus routine surveillance?´ and (2) ³What is 
the expected incremental QALY gain for olaparib versus routine surveillance?´ With respect to the 
first question, the ERG used a restricted means approach to estimate the area under the curve (AUC) 
using the ERG-fitted parametric models of crossover-adjusted OS for olaparib versus placebo. With 
respect to the second question, the ERG developed a partitioned survival model in which parametric 
curves were fitted directly to the crossover-adjusted OS data. Uncertainty was explored across 108 
combinations of candidate parametric functions. 
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3.3.2 Restricted mean survival  
The most optimistic estimate of undiscounted incremental survival benefit for olaparib versus routine 
VXUYHLOODQFHSURGXFHGE\WKH(5*¶VUHVWULFWHGPHDQVDQDO\VLVZDV0.68 life years; this is considerably 
lower than the 1.36 additional life years predicted by the FRPSDQ\¶VPRGHO 
 
3.3.3 Partitioned survival model 
7KH (5*¶V SDUWitioned survival model suggests that the most optimistic discounted incremental 
QALY gain for olaparib versus routine surveillance is approximately 0.52 QALYs (see 
Supplementary Appendix). This is markedly lower than the FRPSDQ\¶V PRGHOOHG HVWLPDWH RI 0.90 
QALYs. Assuming that the FRPSDQ\¶V HVWLPDWHG incremental costs of olaparib are reasonable, this 
implies that the ICER for olaparib versus routine surveillance is likely to be in excess of £92,214 per 
QALY gained, but may be considerably higher. Undiscounted OS in the placebo group was 
consistently greater than 2-years irrespective of the selected survivor function. 
 
3.4 Conclusion of the ERG report 
The ERG considered the evidence for olaparib for the maintenance treatment of BRCA1/2m PSR OC 
to be relatively weak and at relatively high risk of bias. 7KH (5* GLG QRW FRQVLGHU WKH FRPSDQ\¶V
ICERs to be credible. Additional work undertaken by the ERG suggested that the ICER for olaparib 
versus routine surveillance is likely to be greater than £92,214 per QALY gained. On the basis of the 
(5*¶VH[SORUDWRU\DQDO\VHVDQGWKHFRPSDQ\¶VPRGHO-predicted OS for the routine surveillance group 
DSSUR[LPDWHO\PRQWKVRODSDULEGRHVQRWDSSHDUWRVDWLVI\1,&(¶VEoL criteria. 
 
4. KEY METHODOLOGICAL ISSUES 
Study 19 was subject to several methodological issues. The hypothesis that olaparib has superior 
efficacy in BRCAm SDWLHQWVFRPSDUHGZLWKRWKHUSDWLHQWVKDGQRWLQWKH(5*¶VYLHZEHHQUREXVWO\
tested or proved and no Phase III trial was available to confirm results. Whilst the HR for PFS 
suggested a considerable treatment effect, administration of olaparib was not in accordance with its 
licence or with clinical practice in England, and outcomes were at risk of internal and external bias. 
The immaturity of OS data made it difficult to conclude whether PFS advantages would translate into 
improved survival. The ERG considered that WKHFRPSDQ\¶Vmodel did not handle competing risks of 
events or treatment crossover in an unbiased manner. The model appears to over-predict OS for 
olaparib and under-predict OS for routine surveillance. Directly modelling crossover-adjusted OS data 
from Study 19 indicated a markedly smaller incremental survival gain compared with WKHFRPSDQ\¶V
modelled predictions. Consequently, the ICER for olaparib is likely to be considerably higher than 
WKDWVXJJHVWHGE\WKHFRPSDQ\¶VPRGHO. 
 
5. NICE GUIDANCE 
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The Appraisal Committee reviewed the data available on the clinical and cost-effectiveness of 
olaparib, having considered evidence on the nature of recurrent OC and the value placed on the 
benefits of olaparib by people with the condition, those who represent them, and clinical experts. It 
also took into account the effective use of NHS resources. The first ACD (published June 2015) did 
not recommend olaparib for the treatment of BRCAm PSR OC [22]. The Committee noted that 
substantial disagreement between the results from Study 19 and the model predictions undermined 
FRQILGHQFHLQWKHFRPSDQ\¶VPRGHOWKDWWKHPRGHORYHU-predicted the survival gains associated with 
olaparib, and that olaparib did not satisfy 1,&(¶V EoL criteria. The Committee considered that the 
FRPSDQ\¶VVHFRQGDU\analysis did not produce a valid cost-effectiveness estimate. 
 
Following the first ACD, the company submitted additional analyses, including further survival 
modelling using CSE-adjusted OS data [38]. Despite being based on similar data, WKHFRPSDQ\¶VQHZ
survival models did not reflect those produced in WKH(5*¶VH[SORUDWRU\DQDO\VHV; in one example, the 
FRPSDQ\¶V26HVWLPDWHZDVDOPRVWGRXEOHWKDWHVWLPDWHGE\WKH(5*. The ERG was concerned that 
WKHFRPSDQ\¶VQHZVXUYLYDOPRGHOVKDGEHHQLPSOHPHQWHG incorrectly [4]. At the second ACD, the 
Committee was minded not to recommend olaparib for patients who have had 3 or more courses of 
platinum-based chemotherapy; within this subgroup, the Committee requested from the company a 
robust estimate of the cost-effectiveness of olaparib taking account of the cost of somatic testing and 
WDNLQJLQWRDFFRXQWWKH&RPPLWWHH¶VFRQFHUQVDERXWLWVSUHYLRXVPRGHOV7KHFRPSDQ\subsequently 
produced additional analyses for this subgroup, including the lower price for olaparib and a reduction 
in the number of cycles from which olaparib would be provided free of charge (15 rather than 18 
cycles) [39]. The ERG remained concerned that the FRPSDQ\¶Vnew modelled OS predictions in the 
third- and subsequent-line subgroup still did not reflect the observed Study 19 OS data [5]. However, 
the Committee concluded that within this subgroup, the most plausible ICER was approximately 
£46,600 to £46,800 per QALY gained and that there was sufficient evidence to suggest that olaparib 
satisfied 1,&(¶V(R/criteria [40]. 
 
In December 2015, NICE published its FAD which states tKDW³Rlaparib is recommended within its 
marketing authorisation as an option for treating adults with PSR ovarian, fallopian tube or peritoneal 
cancer who have BRCA1 or BRCA2 mutations and whose disease has responded to platinum-based 
chemotherapy only if: they have had 3 or more courses of platinum-based chemotherapy, and; the 
drug cost of olaparib for people who remain on treatment after 15 months will be met by the 
company´ [40].  
 
5.1 Consideration of clinical and cost-effectiveness issues 
This section discusses the key issues considered by the Appraisal Committee. The full list can be 
found in the FAD [40]. 
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5.1.1. Uncertainty surrounding validity of the BRCA1/2 subgroup 
The Committee noted that the key clinical effectiveness evidence was derived the Study 19 BRCAm 
subgroup. It also heard from the company that most of the trial population had been tested for BRCAm 
retrospectively. The Committee noted comments from the ERG that interaction tests between the 
BRCAm subgroup and the whole population were inconclusive, hence it was not possible to be certain 
that the treatment effect was different in the BRCAm subgroup. The Committee heard that there is a 
biologically plausible reason why people with BRCAm disease would benefit more from olaparib than 
the whole trial population, which could be explained by the relationship between malfunctioning 
BRCA genes and the development of HRD, and the subsequent effect on DNA repair. The Committee 
concluded that olaparib was clinically effective in the treatment of PSR OC and accepted that there is 
a biologically plausible reason for olaparib being particularly effective in the BRCAm subgroup. 
 
5.1.2 Uncertainty surrounding the size of the treatment effect estimates 
The Committee noted that olaparib was associated with statistically significant improvements in 
median PFS, TFST/D and TSST/D compared with placebo in the BRCAm subgroup and the whole 
trial population. The Committee concluded that whilst relevant, TFST/D and TSST/D had been 
identified post hoc and should be viewed with caution. It also noted that the OS data were immature 
and may have been confounded by crossover. The Committee noted that without adjustment, the 
difference between treatment groups in median OS in the BRCAm subgroup was 3 months (not 
statistically significant) but if crossover sites were excluded, this resulted in a statistically significant 
difference in median OS of 8.3 months. It concluded that there remained uncertainty about the extent 
to which olaparib increases OS compared with placebo in patients with BRCAm OC. 
 
The Committee considered WKHFRPSDQ\¶V further evidence relating to BRCAm patients in Study 19 
who had received 3 or more lines of platinum-containing therapy. The Committee noted that this 
subgroup contained fewer patients than the total BRCAm subgroup and that there were imbalances in 
baseline characteristics, some of which potentially favoured placebo and others which potentially 
favoured olaparib. Nevertheless, the PFS benefit in this subgroup was 6.9 months (HR=0.11), and the 
median CSE-adjusted OS benefit was 12.3 months (HR=0.56). The Committee noted clinical experts¶ 
comments that a difference of this magnitude had never previously been seen in OC treatment. The 
Committee concluded that there was evidence of benefit for olaparib in patients who had received 
three or more lines of platinum-based chemotherapy. 
 
5.1.3 Uncertainties relating to the cost-effectiveness of olaparib in the BRCAm subgroup 
The Committee considered WKHFRPSDQ\¶VPRGHOVWUXFWXUHto be unconventional and very different to 
those used in previous appraisals. The Committee expressed concern that PFS data from Study 19 had 
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not been included, despite this being the primary outcome in Study 19. In addition, OS data had not 
been directly incorporated into the model. The Committee was concerned that intermediate outcomes 
had been used to make assumptions about longer-term OS, and considered that it would have been 
more conventional to fit a curve directly to the OS data, with adjustment for placebo group crossover. 
The Committee concluded that the company's model was a novel design that lacked external validity, 
and that the use of sequential intermediate outcomes to model OS relied on numerous assumptions 
that may not all be reasonable. It also noted that graphical plots of survival probabilities from the 
model showed that the difference between the curves for olaparib and placebo increased at later time 
points, implying OS benefits for olaparib increase over time. The Committee noted that no data were 
provided to support this and that greater separation of the curves over time would not be expected 
during treatment for cancer. The Committee also noted that the substantial disagreement between the 
UHVXOWVIURP6WXG\DQGWKHPRGHOSUHGLFWLRQVXQGHUPLQHGFRQILGHQFHLQWKHFRPSDQ\¶Vmodel. The 
&RPPLWWHH FRQFOXGHG WKDW WKH FRPSDQ\¶V PRGHOOLQJ RI EHQHILW IRU WKe BRCAm subgroup 
overestimated the benefit of olaparib and therefore underestimated the ICER for olaparib. 
 
5.1.4 Cost-effectiveness of olaparib in the third- and subsequent-line subgroup 
The Committee considered the additional cost-effectiveness analyses provided by the company 
following the second ACD, which related to the subgroup of BRCAm patients who had received 3 or 
more lines of platinum-EDVHGFKHPRWKHUDS\7KH&RPPLWWHHFRQFOXGHGWKDWWKHFRPSDQ\¶VKHDOWK-
state (partitioned survival) model provided a better basis for decision-making than their original 
model. It noted that the ICERs in this subgroup varied according to the curve used to model OS and, 
although it considered that on visual inspection the Gompertz curve might be an option, it heard from 
the company that the log normal and log logistic curves provided the best fit to the data. The 
Committee accepted that this was not unreasonable and concluded that the most plausible ICERs were 
£46,600 to £46,800 per QALY gained. The Committee considered whether the EoL criteria would 
apply to third- and subsequent-line subgroup. It understood that median CSE-adjusted OS for this 
subgroup in the placebo arm of Study 19 was 20.6 months. The Committee was persuaded that the life 
expectancy of people who had received 3 or more lines of platinum-based chemotherapy was likely to 
be less than 24 months. 
 
$335$,6$/&200,77((¶6.(<&21&/86,21 
The Committee concluded that in Study 19, olaparib increased PFS and time to subsequent therapy 
compared with placebo, in the whole trial population and in the BRCAm subgroup. It also concluded 
that there was uncertainty about whether, and to what extent, olaparib increases OS compared with 
placebo. The Committee concluded that the ICERs presented by the company for olaparib compared 
with routine surveillance for the overall population of patients with BRCAm PSR OC were 
considerably above the range normally considered to be a cost-effective use of NHS resources 
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(£20,000 to £30,000 per QALY gained). The Committee concluded that the EoL criteria did not apply 
to olaparib when considering the overall BRCAm PSR OC population. For the subgroup of patients 
with BRCAm PSR who have received 3 or more previous lines of platinum-based chemotherapy, the 
Committee accepted that the most plausible ICERs were £46,600 to £46,800 per QALY gained. The 
Committee concluded that there was sufficient evidence to suggest that olaparib met the EoL criteria 
for this subgroup. 
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Figure 1: Outcome measurement in Study 19 
 
 
 
 
 
 
 
 
R - randomisation; PFS - progression-free survival; TFST - time to first subsequent therapy; PFS2 - 
second progression-free survival interval; TSST - time to second subsequent therapy; OS - overall 
survival; HRQoL ± health-related quality of life; TTD - time to treatment discontinuation. 
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Supplementary appendix: ERG exploratory analysis results ± incremental QALY gains based 
on (5*¶VSDUWLWLRQHGVXUYLYDOPRGHO 
Scenario Survivor function Mean QALYs Incremental 
QALYs 
(olaparib vs 
routine 
surveillance) 
Time to 
treatment 
discontinuation  
Time to first 
subsequent 
therapy Overall survival 
Olaparib Routine 
surveillance 
1 gen. gamma gen. gamma RPSFTM gen. F 2.16 2.54 -0.38 
2 gen. gamma gen. gamma RPSFTM gen. gamma 2.16 2.36 -0.20 
3 gen. gamma gen. gamma RPSFTM gamma 2.20 1.92 0.28 
4 gen. gamma gen. gamma RPSFTM log normal 2.44 2.16 0.27 
5 gen. gamma gen. gamma RPSFTM log logistic 2.40 2.17 0.23 
6 gen. gamma gen. gamma RPSFTM Weibull 2.10 1.87 0.23 
7 gen. gamma gen. gamma CSE gen. F 2.36 2.80 -0.44 
8 gen. gamma gen. gamma CSE gen. gamma 2.35 2.80 -0.45 
9 gen. gamma gen. gamma CSE gamma 2.32 1.93 0.40 
10 gen. gamma gen. gamma CSE log normal 2.63 2.15 0.48 
11 gen. gamma gen. gamma CSE log logistic 2.57 2.16 0.41 
12 gen. gamma gen. gamma CSE Weibull 2.20 1.90 0.30 
13 log normal gen. gamma RPSFTM gen. F 2.16 2.53 -0.37 
14 log normal gen. gamma RPSFTM gen. gamma 2.16 2.35 -0.19 
15 log normal gen. gamma RPSFTM gamma 2.20 1.91 0.29 
16 log normal gen. gamma RPSFTM log normal 2.44 2.15 0.29 
17 log normal gen. gamma RPSFTM log logistic 2.40 2.16 0.24 
18 log normal gen. gamma RPSFTM Weibull 2.10 1.86 0.24 
19 log normal gen. gamma CSE gen. F 2.36 2.79 -0.43 
20 log normal gen. gamma CSE gen. gamma 2.35 2.79 -0.44 
21 log normal gen. gamma CSE gamma 2.32 1.92 0.41 
22 log normal gen. gamma CSE log normal 2.63 2.14 0.49 
23 log normal gen. gamma CSE log logistic 2.57 2.15 0.43 
24 log normal gen. gamma CSE Weibull 2.20 1.89 0.31 
25 log logistic gen. gamma RPSFTM gen. F 2.16 2.53 -0.37 
26 log logistic gen. gamma RPSFTM gen. gamma 2.16 2.35 -0.19 
27 log logistic gen. gamma RPSFTM gamma 2.20 1.91 0.29 
28 log logistic gen. gamma RPSFTM log normal 2.44 2.15 0.28 
29 log logistic gen. gamma RPSFTM log logistic 2.40 2.16 0.24 
30 log logistic gen. gamma RPSFTM Weibull 2.10 1.86 0.24 
31 log logistic gen. gamma CSE gen. F 2.35 2.79 -0.43 
32 log logistic gen. gamma CSE gen. gamma 2.35 2.79 -0.44 
33 log logistic gen. gamma CSE gamma 2.32 1.92 0.41 
34 log logistic gen. gamma CSE log normal 2.62 2.13 0.49 
35 log logistic gen. gamma CSE log logistic 2.57 2.14 0.43 
36 log logistic gen. gamma CSE Weibull 2.20 1.89 0.31 
37 gen. gamma log normal RPSFTM gen. F 2.17 2.52 -0.35 
38 gen. gamma log normal RPSFTM gen. gamma 2.17 2.34 -0.17 
39 gen. gamma log normal RPSFTM gamma 2.21 1.91 0.30 
40 gen. gamma log normal RPSFTM log normal 2.45 2.14 0.31 
41 gen. gamma log normal RPSFTM log logistic 2.41 2.16 0.26 
42 gen. gamma log normal RPSFTM Weibull 2.10 1.86 0.24 
43 gen. gamma log normal CSE gen. F 2.37 2.78 -0.41 
44 gen. gamma log normal CSE gen. gamma 2.36 2.78 -0.42 
45 gen. gamma log normal CSE gamma 2.33 1.92 0.42 
46 gen. gamma log normal CSE log normal 2.65 2.13 0.52 
47 gen. gamma log normal CSE log logistic 2.59 2.14 0.45 
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Scenario Survivor function Mean QALYs Incremental 
QALYs 
(olaparib vs 
routine 
surveillance) 
Time to 
treatment 
discontinuation  
Time to first 
subsequent 
therapy Overall survival 
Olaparib Routine 
surveillance 
48 gen. gamma log normal CSE Weibull 2.22 1.89 0.32 
49 log normal log normal RPSFTM gen. F 2.17 2.53 -0.35 
50 log normal log normal RPSFTM gen. gamma 2.17 2.34 -0.18 
51 log normal log normal RPSFTM gamma 2.21 1.92 0.29 
52 log normal log normal RPSFTM log normal 2.45 2.15 0.31 
53 log normal log normal RPSFTM log logistic 2.41 2.16 0.25 
54 log normal log normal RPSFTM Weibull 2.10 1.86 0.24 
55 log normal log normal CSE gen. F 2.37 2.78 -0.42 
56 log normal log normal CSE gen. gamma 2.36 2.79 -0.42 
57 log normal log normal CSE gamma 2.33 1.92 0.41 
58 log normal log normal CSE log normal 2.65 2.13 0.52 
59 log normal log normal CSE log logistic 2.59 2.15 0.45 
60 log normal log normal CSE Weibull 2.22 1.90 0.32 
61 log logistic log normal RPSFTM gen. F 2.17 2.52 -0.35 
62 log logistic log normal RPSFTM gen. gamma 2.17 2.34 -0.18 
63 log logistic log normal RPSFTM gamma 2.21 1.91 0.29 
64 log logistic log normal RPSFTM log normal 2.45 2.14 0.31 
65 log logistic log normal RPSFTM log logistic 2.41 2.16 0.25 
66 log logistic log normal RPSFTM Weibull 2.10 1.86 0.24 
67 log logistic log normal CSE gen. F 2.36 2.78 -0.42 
68 log logistic log normal CSE gen. gamma 2.36 2.78 -0.42 
69 log logistic log normal CSE gamma 2.33 1.92 0.41 
70 log logistic log normal CSE log normal 2.64 2.13 0.52 
71 log logistic log normal CSE log logistic 2.59 2.14 0.44 
72 log logistic log normal CSE Weibull 2.21 1.89 0.32 
73 gen. gamma log logistic RPSFTM gen. F 2.17 2.52 -0.35 
74 gen. gamma log logistic RPSFTM gen. gamma 2.17 2.34 -0.17 
75 gen. gamma log logistic RPSFTM gamma 2.21 1.91 0.30 
76 gen. gamma log logistic RPSFTM log normal 2.45 2.14 0.31 
77 gen. gamma log logistic RPSFTM log logistic 2.41 2.15 0.26 
78 gen. gamma log logistic RPSFTM Weibull 2.10 1.86 0.24 
79 gen. gamma log logistic CSE gen. F 2.37 2.78 -0.41 
80 gen. gamma log logistic CSE gen. gamma 2.36 2.78 -0.42 
81 gen. gamma log logistic CSE gamma 2.33 1.92 0.42 
82 gen. gamma log logistic CSE log normal 2.65 2.13 0.52 
83 gen. gamma log logistic CSE log logistic 2.59 2.14 0.45 
84 gen. gamma log logistic CSE Weibull 2.22 1.89 0.33 
85 log normal log logistic RPSFTM gen. F 2.17 2.52 -0.35 
86 log normal log logistic RPSFTM gen. gamma 2.17 2.34 -0.17 
87 log normal log logistic RPSFTM gamma 2.21 1.91 0.30 
88 log normal log logistic RPSFTM log normal 2.45 2.15 0.31 
89 log normal log logistic RPSFTM log logistic 2.41 2.16 0.25 
90 log normal log logistic RPSFTM Weibull 2.10 1.86 0.24 
91 log normal log logistic CSE gen. F 2.37 2.78 -0.42 
92 log normal log logistic CSE gen. gamma 2.36 2.78 -0.42 
93 log normal log logistic CSE gamma 2.33 1.92 0.41 
94 log normal log logistic CSE log normal 2.65 2.13 0.52 
95 log normal log logistic CSE log logistic 2.59 2.15 0.45 
96 log normal log logistic CSE Weibull 2.22 1.90 0.32 
97 log logistic log logistic RPSFTM gen. F 2.17 2.52 -0.35 
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Scenario Survivor function Mean QALYs Incremental 
QALYs 
(olaparib vs 
routine 
surveillance) 
Time to 
treatment 
discontinuation  
Time to first 
subsequent 
therapy Overall survival 
Olaparib Routine 
surveillance 
98 log logistic log logistic RPSFTM gen. gamma 2.17 2.34 -0.17 
99 log logistic log logistic RPSFTM gamma 2.21 1.91 0.30 
100 log logistic log logistic RPSFTM log normal 2.45 2.14 0.31 
101 log logistic log logistic RPSFTM log logistic 2.41 2.16 0.25 
102 log logistic log logistic RPSFTM Weibull 2.10 1.86 0.24 
103 log logistic log logistic CSE gen. F 2.36 2.78 -0.42 
104 log logistic log logistic CSE gen. gamma 2.36 2.78 -0.42 
105 log logistic log logistic CSE gamma 2.33 1.92 0.41 
106 log logistic log logistic CSE log normal 2.64 2.13 0.52 
107 log logistic log logistic CSE log logistic 2.59 2.14 0.44 
108 log logistic log logistic CSE Weibull 2.21 1.89 0.32 
QALY ± quality-adjusted life year; gen.± generalised; RPSFTM ± Rank Preserving Structural Failure Time Model; CSE ± 
crossover sites excluded 
 
 
 
